DOCSLIB.ORG

Targeted Therapy Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeted Therapy Inflammation Targeted Therapy Clinical Proof of Concept Pivotal Marketed Immuno-Oncology Clinical Proof of Concept Pivotal Marketed ® 1 13 Jakafi (ruxolitinib) Myelofibrosis2, polycythemia vera3, acute graft-versus-host disease (GVHD)4 retifanlimab Squamous cell anal carcinoma, non-small cell lung cancer (NSCLC) JAK1/JAK2 U.S. PD-1 ® 13 Pemazyre (pemigatinib) 5 retifanlimab Cholangiocarcinoma U.S. MSI-H endometrial cancer, Merkel cell carcinoma FGFR1/2/3 PD-1 ® 6,7 Monjuvi (tafasitamab-cxix) 8 INCB86550 Diffuse large B-cell lymphoma U.S. Solid tumors CD19 PD-L1 ® 9 14 Iclusig (ponatinib) 10 11 MCLA-145 Chronic myeloid leukemia , Ph+ acute lymphoblastic leukemia EUROPE Solid tumors BCR-ABL PD-L1xCD137 ruxolitinib12 epacadostat Chronic GVHD, COVID-19 associated cytokine storm Multiple tumor types JAK1/JAK2 IDO1 ruxolitinib + parsaclisib INCB0115815 Myelofibrosis Multiple tumor types JAK1/JAK2, PI3Kδ ARG itacitinib INCAGN187616 Chronic GVHD Solid tumors JAK1 GITR pemigatinib INCAGN194916 Bladder cancer, solid tumors, 8p11 myeloproliferative neoplasms Solid tumors FGFR1/2/3 OX40 parsaclisib INCAGN239016 Follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma Solid tumors PI3Kδ TIM-3 INCB57643 INCAGN238516 Myelofibrosis Multiple tumor types BET LAG-3 INCB00928 INCB81776 Myeloproliferative disorders Multiple tumor types ALK2 AXL/MER tafasitamab7 Chronic lymphocytic leukemia CD19 Inflammation/ Autoimmunity Partnered ® 17 ruxolitinib cream Olumiant (baricitinib) 18 Atopic dermatitis, vitiligo Rheumatoid arthritis JAK1/JAK2 JAK1/JAK2 19 INCB00928 Tabrecta™ (capmatinib) 20 Fibrodysplasia ossificans progressiva NSCLC with METex14 ALK2 MET INCB54707 baricitinib17 Hidradenitis suppurativa Atopic dermatitis, systemic lupus erythematosus, alopecia areata, COVID-19 JAK1 JAK1/JAK2 parsaclisib capmatinib19 Autoimmune hemolytic anemia Liver cancer PI3Kδ MET Updated as of August 4, 2020 1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute GVHD 5. Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test 6. Co-commercialization in the U.S. with MorphoSys 7. Development in collaboration with MorphoSys 8. In combination with lenalidomide in adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant 9. European rights to Iclusig licensed from ARIAD 10. Adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 11. Adults with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 12. Certain development programs conducted in collaboration with Novartis 13. In collaboration with MacroGenics 14. In collaboration with Merus 15. Co-development with Calithera 16. Discovery collaboration with Agenus 17. Worldwide rights to baricitinib licensed to Lilly 18. Approved in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 19. Worldwide rights to capmatinib licensed to Novartis 20. Approved in the U.S. and Japan for certain patients with NSCLC with MET exon 14 skipping (METex14) mutation © 2020, Incyte Biosciences International Sàrl. All rights reserved: August 2020: CH/OTHR/M/20/0008. For the medical part of the virtual booth. The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation..
Load more

Recommended publications
  • Tabrecta (Capmatinib)
    Tabrecta (capmatinib) NEW PRODUCT SLIDESHOW Introduction . Brand name: Tabrecta . Generic name: Capmatinib . Pharmacologic class: Kinase inhibitor . Strength and Formulation: 150mg, 200mg; tablets . Manufacturer: Novartis . How supplied: Tabs—56 . Legal Classification: Rx Tabrecta Indication Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA- approved test . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) Dosage and Administration Confirm presence of a mutation that leads to MET exon 14 skipping in tumor specimens Swallow whole 400mg twice daily Recommended dose reductions for adverse reactions: . First: 300mg twice daily . Second: 200mg twice daily . Permanently discontinue in patients unable to tolerate 200mg twice daily Dosage Modifications for Adverse Reactions Interstitial lung disease/pneumonitis . Any grade: permanently discontinue Increased ALT and/or AST without increased total bilirubin . Grade 3: withhold until recovery to baseline ALT/AST; if recovery to baseline within 7 days, then resume at same dose, otherwise resume at a reduced dose . Grade 4: permanently discontinue Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis . ALT and/or AST >3xULN with total bilirubin >2xULN: permanently discontinue Dosage Modifications for Adverse Reactions Increased total bilirubin without concurrent increased ALT and/or AST . Grade 2: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at same dose, otherwise resume at reduced dose . Grade 3: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at reduced dose, otherwise permanently discontinue .
    [Show full text]
  • Incyte Corporation
    Building Value through Innovative Medicines 2019 First Quarter Financial and Corporate Update April 30, 2019 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding ruxolitinib, ruxolitinib cream, itacitinib, pemigatinib, parsaclisib and INCMGA0012 trial results and timing of the receipt and presentation of those results; the expected timing of the NDA submissions for pemigatinib and capmatinib; our belief that certain of our projects, such as the acceleration of vitiligo development and opportunities with pemigatinib and itacitinib, warrant increased near-term funding; expectations regarding planned regulatory updates, planned pivotal clinical updates and planned clinical trial initiations; expectations by our collaborative partners regarding timing of NDA submission for capmatinib and announcement of baricitinib trial results; our plans and expectations for development of, and clinical trials involving, our other product candidates, including the potential timing for regulatory submissions; our plans for immediate launch of ruxolitinib for steroid-refractory acute GVHD should the FDA approve our sNDA; our updated 2019 GAAP and non-GAAP guidance; our expectations regarding baricitinib royalties; and our expected 2019 newsflow events. These forward-looking statements are based on our current expectations and are subject to risks
    [Show full text]
  • First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
    First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations Patients with stage IV non-small cell lung cancer Nonsquamous cell carcinoma and squamous cell carcinoma Activating EGFR mutation other Sensitizing (L858R/exon 19 MET exon 14 skipping than exon 20 insertion mutations, EGFR exon 20 mutation ALK rearrangement ROS1 rearrangement BRAF V600E mutation RET rearrangement NTRK rearrangement mutations KRAS alterations HER2 alterations NRG1 alterations deletion) EGFR mutation T790M, L858R or Ex19Del PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Emerging target; no Emerging target; no Emerging target; no Platinum doublet † † † Osimertinib monotherapy S Afatinib monotherapy M M Alectinib S Entrectinib M Dabrafenib/trametinib M Capmatinib M Selpercatinib M Entrectinib M conclusions available conclusions available conclusions available chemotherapy ± bevacizumab Gefitinib with doublet Standard treatment based on Standard treatment based on Standard treatment based on M M M Brigatinib S Crizotinib M M Tepotinib M Pralsetinib* W Larotrectinib M chemotherapy non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline If alectinib or brigatinib are not available If entrectinib or crizotinib are not available Standard treatment based on Standard treatment based on Standard treatment based on Dacomitinib monotherapy M Osimertinib W M M M Ceritinib S Ceritinib W non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline Monotherapy with afatinib M Crizotinib S Lortlatinib W Standard treatment based on Erlotinib/ramucirumab M M non-driver mutation guideline Erlotinib/bevacizumab M Monotherapy with erlotinib M Strength of Recommendation Monotherapy with gefitinib M S Strong M Moderate W Weak Monotherapy with icotinib M Notes.
    [Show full text]
  • Capmatinib) Tablets, for Oral Use  Hepatotoxicity: Monitor Liver Function Tests
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS----------------------­ These highlights do not include all the information needed to use Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening TABRECTA safely and effectively. See full prescribing information for pulmonary symptoms indicative of ILD/pneumonitis. Permanently TABRECTA. discontinue TABRECTA in patients with ILD/pneumonitis. (2.3, 5.1) TABRECTATM (capmatinib) tablets, for oral use Hepatotoxicity: Monitor liver function tests. Withhold, dose reduce, or Initial U.S. Approval: 2020 permanently discontinue TABRECTA based on severity. (2.3, 5.2) Risk of Photosensitivity: May cause photosensitivity reactions. Advise ----------------------------INDICATIONS AND USAGE------------------------­ patients to limit direct ultraviolet exposure. (5.3) TABRECTA is a kinase inhibitor indicated for the treatment of adult patients Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the with metastatic non-small cell lung cancer (NSCLC) whose tumors have a potential risk to a fetus and to use effective contraception. (5.4, 8.1, 8.3) mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. ------------------------------ADVERSE REACTIONS-----------------------------­ The most common adverse reactions (≥ 20%) are peripheral edema, nausea, This indication is approved under accelerated approval based on overall fatigue, vomiting, dyspnea, and decreased appetite. (6) response
    [Show full text]
  • (CHMP) Agenda for the Meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    22 March 2021 EMA/CHMP/171652/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 22 March 2021, 09:00 – 19:30, virtual meeting/ room 1C 23 March 2021, 08:30 – 19:30, virtual meeting/ room 1C 24 March 2021, 08:30 – 19:30, virtual meeting/ room 1C 25 March 2021, 08:30 – 19:30, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion- Positive Lung Cancer by Combining Selpercatinib with Crizotinib
    Author Manuscript Published OnlineFirst on October 20, 2020; DOI: 10.1158/1078-0432.CCR-20-2278 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. TITLE Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion- positive lung cancer by combining selpercatinib with crizotinib AUTHORS Ezra Y. Rosen1,* , Melissa L. Johnson2,*, Sarah E. Clifford3, Romel Somwar4, Jennifer F. Kherani5, Jieun Son3 Arrien A. Bertram3, Monika A. Davare6, Eric Gladstone4, Elena V. Ivanova7, Dahlia N. Henry5, Elaine M. Kelley3, Mika Lin3, Marina S.D. Milan3, Binoj C. Nair5, Elizabeth A. Olek5, Jenna E. Scanlon3, Morana Vojnic4, Kevin Ebata5, Jaclyn F. Hechtman4, Bob T. Li1,8, Lynette M. Sholl9, Barry S. Taylor10, Marc Ladanyi4, Pasi A. Jänne3, S. Michael Rothenberg5, Alexander Drilon1,8,*, and Geoffrey R. Oxnard3,* *These authors contributed equally AFFILIATIONS 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York NY 2. Department of Medicine, Sarah Cannon Cancer Center, Nashville, TN 3. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York NY 5. Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, CT 6. Oregon Health and Science University, Portland, OR 7. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 8. Weill Cornell Medical College, New York NY 9. Department of Pathology, Brigham and Women’s
    [Show full text]
  • Data from Incyte's Oncology Portfolio Accepted for Presentation at The
    5/19/2021 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021. “We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Ocer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.” Key abstracts accepted by ASCO include: Oral Presentations Ponatinib OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1(Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.) Poster Discussions Tafasitamab Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diuse Large B-cell Lymphoma 1 (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.) Capmatinib Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3(Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.) ePosters Capmatinib Capmatinib Ecacy in Patients with NSCLC Identied as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3(Abstract #9111.
    [Show full text]
  • NCCN Guidelines for Central Nervous System Cancers Cancer V.1.2021 – Annual 10/23/2020
    NCCN Guidelines for Central Nervous System Cancers Cancer v.1.2021 – Annual 10/23/2020 Guideline Page Institution Vote Panel Discussion/References and Request YES NO ABSTAIN ABSENT GLIO-1, GLIO-5 Based on a review of the data and discussion, the 0 24 0 5 External request: panel consensus did not support the addition of these specific recommendations into the Guidelines as they Submission/NX Development Corp (06/02/20): agree that this is already covered in the Guideline. For the Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Astrocytoma, Anaplastic Gliomas and Glioblastoma (GLIO-1) workflow, under surgery, we recommend inclusion of Aminolevulinic acid hydrochloride (ALA, Brand Name Gleolan™) as an adjunct for the visualization of malignant tissue and to improve the completeness of resection during fluorescence guided glioma surgery. For the Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Astrocytoma, Anaplastic Gliomas and Glioblastoma (GLIO-5) workflow, under recurrence resection, we recommend inclusion of Aminolevulinic acid hydrochloride (ALA, Brand Name Gleolan™) as an adjunct for the visualization of malignant tissue and to improve the completeness of resection during fluorescence guided glioma surgery. GLIO-2 The panel consensus supported the removal of 24 0 0 5 Internal request: “Standard RT + neoadjuvant or adjuvant PCV” for adjuvant treatment of anaplastic astrocytoma Consider removal of “Standard RT ÷ neoadjuvant or adjuvant PCV” for adjuvant treatment of anaplastic astrocytoma BRAIN-D (1 of 15, 2 of 15, 3 of 15) The panel consensus supported the inclusion of 24 0 0 5 Internal request: larotrectinib and entrectinib for tumors with NTRK gene fusion for recurrent or progressive disease Consider including larotrectinib and entrectinib for under useful in certain circumstances for low-grade NTRK gene fusion tumors.
    [Show full text]
  • Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
    pharmaceuticals Review Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades Mohd. Imran 1,* , Syed Mohammed Basheeruddin Asdaq 2,* , Shah Alam Khan 3 , Dhanalekshmi Unnikrishnan Meenakshi 3, Abdulhakeem S. Alamri 4,5 , Walaa F. Alsanie 4,5, Majid Alhomrani 4,5, Yahya Mohzari 6, Ahmed Alrashed 7, Mohammed AlMotairi 8, Eman H. Alkhaldi 9, Abeer K. Alorabi 10, Ahmed Subeh Alshrari 11, Mohammad Tauseef 12, Abida 1 , Saleh I. Alaqel 1, Ozair Alam 13 and Md. Afroz Bakht 14 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Arar 91911, Saudi Arabia; [email protected] (A.); [email protected] (S.I.A.) 2 Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia 3 College of Pharmacy, National University of Science and Technology, Muscat 130, Oman; [email protected] (S.A.K.); [email protected] (D.U.M.) 4 Department of Clinical Laboratory Sciences, The Faculty of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia; [email protected] (A.S.A.); [email protected] (W.F.A.); [email protected] (M.A.) 5 Centre of Biomedical Sciences Research (CBSR), Deanship of Scientific Research, Taif University, Taif 21944, Saudi Arabia Citation: Imran, M.; Asdaq, S.M.B.; 6 Clinical Pharmacy Department, King Saud Medical City, Riyadh 12746, Saudi Arabia; [email protected] 7 Khan, S.A.; Unnikrishnan Meenakshi, Pharmaceutical Services Administration, Inpatient Department, Main Hospital, King Fahad Medical City, D.; Alamri, A.S.; Alsanie, W.F.; Riyadh 11564, Saudi Arabia; [email protected] 8 Department of Clinical Pharmacy, King Fahad Medical City, Riyadh 11564, Saudi Arabia; Alhomrani, M.; Mohzari, Y.; Alrashed, [email protected] A.; AlMotairi, M.; et al.
    [Show full text]
  • Targeted Therapy for Lung Cancer (Faculty Presentations)
    POST-TEST Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer (Faculty Presentations) THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. Which of the following disease-free 4. Interim results of the Phase II DESTINY- survival outcomes was reported at the Lung01 study, reported at the ASCO20 plenary session of the ASCO20 Virtual Virtual meeting, evaluating the antibody- meeting from the Phase III ADAURA drug conjugate trastuzumab deruxtecan trial evaluating osimertinib as adjuvant demonstrated promising clinical activity therapy for patients with Stage IB to IIIA with a high objective response rate non-small cell lung cancer (NSCLC) with and durable responses in patients with EGFR mutations after complete tumor nonsquamous NSCLC and which of the resection? following targetable mutations? a. Statistically significant and clini- a. ALK gene rearrangements cally meaningful improvement b. EGFR mutations versus placebo c. HER2 mutations b. Trend toward statistically significant d. MET exon 14 skipping mutations improvement versus placebo e. RET fusions c. No improvement versus placebo f. ROS1 rearrangements 2. Which of the following drug types best 5. Which of the following statements is true describes the mechanism of action of with regard to CNS activity in patients the recently FDA-approved agent selper- with NSCLC, ROS-1 rearrangement and catinib for patients with metastatic brain metastases undergoing treatment NSCLC? with a ROS-1 inhibitor? a. ALK inhibitor a. Crizotinib is more efficacious b. EGFR inhibitor than entrectinib c. HER2 inhibitor b. Entrectinib is more efficacious d. MET inhibitor than crizotinib e. RET inhibitor c. Neither a nor b (these agents f. ROS1 inhibitor exhibit equivalent CNS activity) 3.
    [Show full text]
  • Westfield USHP Slides Handout
    A Breath of Fresh Air: New Drugs in Lung Cancer Jaelyn R. Westfield, PharmD Jaelyn R. Westfield, PharmD PGY-2 Hematology/Oncology Pharmacy Resident November 14, 2020 Huntsman Cancer Institute [email protected] 1 2 Disclosure Pharmacist Learning Objectives No Relevant Financial Conflicts of Interest 1. Describe potential side effects of entrectinib, selpercatinib, • CE presenter, Jaelyn R. Westfield, PharmD capmatinib, and lurbinectedin • CE mentor, Courtney C. Cavalieri, PharmD, BCOP 2. Demonstrate understanding of how new agents fit into treatment algorithms for small cell and non-small cell lung cancer Off-Label Uses of Medications: None 3. Compare the mechanism of action of entrectinib, selpercatinib, capmatinib, and lurbinectedin 4 5 Technician Learning Objectives 1. Differentiate preparation processes for lurbinectedin administered through a central versus peripheral line 2. Discuss the role of patient assistance programs for selpercatinib, capmatinib, and entrectinib Introduction to Lung 3. Recognize which new medications used in lung cancer treatment are oral and which are intravenous Cancer 6 7 US Statistics 2017 US Statistics 2017 US Top 5 Cancers by Rates of New Cancer Cases Per 100,000 People 2017 US Top 5 Cancers by Rates of Cancer Deaths Per 100,000 People 2017 Female breast 125.1 Lung and bronchus 36.7 Pr ost at e 106.5 Female breast 19.9 Lung and bronchus 55.2 Pr ostat e 18.9 Colon and rectum 36.8 Colon and rectum 13.5 Corpus and Uterus, NOS 27.2 Pancr eas 11.1 0 20 40 60 80 10 0 12 0 14 0 0 5 10 15 20 25 30 35 40 U.S.
    [Show full text]
  • Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
    EUROPEAN RESPIRATORY REVIEW SERIES ARTICLE P. ABDAYEM AND D. PLANCHARD Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer Pamela Abdayem and David Planchard Number 6 in the Series “Thoracic oncology” Edited by Rudolf Huber and Peter Dorfmüller Dept of Cancer Medicine, Thoracic Group, Gustave Roussy Cancer Campus, Villejuif, France. Corresponding author: David Planchard ([email protected]) Shareable abstract (@ERSpublications) Screening for driver alterations in patients with advanced lung adenocarcinoma and those with squamous cell carcinoma and no/little smoking history is mandatory. Liquid biopsy is evolving constantly and will definitely improve outcomes in thoracic oncology. https://bit.ly/2XjuQrD Cite this article as: Abdayem P, Planchard D. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. Eur Respir Rev 2021; 30: 200294 [DOI: 10.1183/16000617.0294-2020]. Abstract Copyright ©The authors 2021 Personalised medicine, an essential component of modern thoracic oncology, has been evolving continuously ever since the discovery of the epidermal growth factor receptor and its tyrosine kinase This version is distributed under the terms of the Creative inhibitors. Today, screening for driver alterations in patients with advanced lung adenocarcinoma as well as Commons Attribution those with squamous cell carcinoma and no/little history of smoking is mandatory. Multiplex molecular Non-Commercial Licence 4.0. platforms are preferred to sequential molecular testing since they are less time- and tissue-consuming. In For commercial reproduction this review, we present the latest updates on the nine most common actionable driver alterations in rights and permissions contact nonsmall cell lung cancer.
    [Show full text]